Osteoporosis Awareness in Rheumatoid Arthritis Patients

February 21, 2023 updated by: Mustafa Hüseyin Temel, Uskudar State Hospital

Knowledge and Awareness of Osteoporosis in Rheumatoid Arthritis Patients

Osteoporosis is a condition that describes compromised skeletal microarchitecture in general, with clinical signs of decreased bone mineral density. Rheumatoid arthritis patients are at increased risk for developing osteoporosis. It is crucial to identify whether rheumatoid arthritis patients know and know about this disease. This study investigates awareness and knowledge of osteoporosis in rheumatoid arthritis patients.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Osteoporosis is a common disease of bone loss. The reduced bone strength predisposes an increased risk for fractures in older individuals. It can affect people from different ethnicity. Many factors increase the risk of osteoporosis, including age, postmenopausal state, glucocorticoid use, low body weight, calcium, vitamin D, immobility, and chronic inflammation. Patients with rheumatoid arthritis are at high risk of developing osteoporosis due to chronic inflammation and the medications they use. Patients' knowledge and awareness about osteoporosis are essential for early detection, implementation of lifestyle changes, and treatment compliance. This study aimed to investigate osteoporosis awareness and knowledge about osteoporosis in patients with rheumatoid arthritis.

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Turkey
    • Üsküdar
      • Istanbul, Üsküdar, Turkey

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients aged 18 to 90 years with a diagnosis of rheumatoid arthritis who gave consent to participate in the study.

Description

Inclusion Criteria:

  • Clinical diagnosis of rheumatoid arthritis
  • Must be between the ages of 18 and 90
  • Must give consent to participate in the study

Exclusion Criteria:

• Not giving consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Rheumatoid Arthritis Patients
Patients that are diagnosed with rheumatoid arthritis
Other: Patient information form
Patients will be asked to fill out a patient information form and an osteoporosis awareness form

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Level of knowledge in osteoporosis
Time Frame: 1 day
Level of knowledge in osteoporosis will be assessed with revised osteoporosis knowledge test (OKT). The Revised OKT (2012) is a comprehensive instrument reflecting current research and assesses osteoporosis knowledge of adults. Responses offered to participants are multiple choice (e.g., for risk items: more likely, less likely, neutral, don't know), there is only one correct answer for each item. Responses are dichotomously recoded as correct or incorrect. In a U.S. sample of adults, the measure demonstrated internal consistency, very good stability, and content validity. Point-biserial correlations supported the measure's validity.
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Uskudar State Hospital

Investigators

  • Study Chair: Mustafa H Temel, M.D., Üsküdar State Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

April 30, 2023

Primary Completion (Anticipated)

July 30, 2023

Study Completion (Anticipated)

August 30, 2023

Study Registration Dates

First Submitted

December 27, 2022

First Submitted That Met QC Criteria

February 21, 2023

First Posted (Estimate)

February 22, 2023

Study Record Updates

Last Update Posted (Estimate)

February 22, 2023

Last Update Submitted That Met QC Criteria

February 21, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OPRA1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rheumatoid Arthritis

Clinical Trials on Patient information form

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe